Replies to post #741313 on NorthWest Biotherapeutics Inc (NWBO)

[antihama]

Interesting article. As LP already knows, the MHRA is still a player after BREXIT.

Almost three quarters of pharmaceutical and biotech C-suite executives in the 2021 survey stated that the UK will remain a first or early medicines launch destination, meaning National Health Service patients will be amongst the first in the world to access innovative new medicines.

65 percent of C-Suite respondents are aware of the MHRA’s new regulatory and access initiatives, with 34 percent confirming the MHRA as its priority regulator, and 22 percent planning to submit for licensing to the European Medicines Agency and the MHRA simultaneously. These results cement the MHRA’s position as a leading global regulatory authority. This is despite the UK’s exit from the European Union.

About the author (IQVIA)

IQVIA United Kingdom
IQVIA is a world leader in using data, technology, advanced analytics and human expertise to help customers drive healthcare - and human health - forward. Together with the life sciences and NHS stakeholders we serve, we are enabling a more modern, more effective and more efficient healthcare system, and creating breakthrough solutions that transform business and patient outcomes.
Real-World Evidence. Real Confidence. Real Results.
IQVIA Real World Solutions is the proven partner for real-world evidence that meets stakeholder needs with confidence, delivering real impact for clients, clinicians and patients.

I would say they got a foot in the door regarding the state of the business.

Happy New Year to all (yes, even to the Bashers)!